Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protogenin (PRTG) is a single-pass transmembrane protein belonging to the immunoglobulin superfamily, specifically the DCC/neogenin subclass. Structurally, it contains four immunoglobulin-like domains, five fibronectin type III repeats, a signal peptide, and a cytoplasmic domain. During embryogenesis, PRTG is highly expressed in neural, craniofacial, and epithelial tissues where it regulates organ patterning and suppresses premature neuronal differentiation, preserving neural progenitor states. PRTG can dimerize and acts as a cell membrane receptor; its endogenous ligand is the secreted ERdj3 protein. Knockdown or inhibition of PRTG leads to increased neurogenesis and disrupted morphogenesis in multiple tissues. Although not implicated as a therapeutic target, PRTG has been linked genetically with neurodevelopmental conditions and is essential for correct vertebral and craniofacial patterning through modulation of TGFβ signaling and HOX gene activation[1][2][3].
Not established for any drugs. Experimentally, endogenous ligand is ERdj3, a stress-inducible protein that binds to PRTG and modulates neurogenesis through PRTG signaling[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protogenin (PRTG).